San Rocco Therapeutics, formerly known as Errant Gene Therapeutics, is a Chicago-based biotechnology company dedicated to developing therapies for life-threatening rare diseases. Founded in 1992 by Patrick Girondi, whose son was diagnosed with Thalassemia, the company has been at the forefront of gene therapy research. With a team of researchers, doctors, and collaborators from renowned institutions worldwide, San Rocco Therapeutics aims to bring affordable gene therapy options to patients suffering from rare and orphan diseases.
Specializing in diseases such as Sickle Cell Disease and Beta Thalassemia, San Rocco Therapeutics is committed to finding innovative solutions to improve the lives of millions affected by these conditions. Inspired by the patron saint of hopeless disease, San Rocco, the company strives to follow his example of benevolence and compassion in the face of adversity. Through their dedication to research and patient well-being, San Rocco Therapeutics is making significant strides in the field of gene therapy.
Generated from the website